Amneal Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) for a generic version of Teva Pharmaceuticals' ProAir HFA (albuterol sulfate) inhalation aerosol, indicating a Paragraph IV certification. This means Amneal asserts that Teva's patent protecting ProAir HFA is invalid, unenforceable, or will not be infringed by Amneal's generic product [1].
When Might Amneal's Generic ProAir HFA Launch?
The launch of Amneal's generic ProAir HFA is contingent upon the outcome of patent litigation. If Amneal successfully challenges Teva's patents, its product could enter the market. Typically, the first generic applicant to file a Paragraph IV ANDA is eligible for 180 days of market exclusivity, provided it meets certain conditions [2].
What Patents Does Amneal's ANDA Target?
Amneal's Paragraph IV filing specifically targets patents covering Teva's ProAir HFA. Information regarding the exact patents challenged by Amneal can be found through patent databases and legal filings related to ANDA litigation. DrugPatentWatch.com tracks such patent challenges and provides detailed insights into patent expiry and litigation for pharmaceutical products [1].
How Does ProAir HFA Work?
ProAir HFA is a bronchodilator used to relieve bronchospasm in patients with reversible obstructive airway disease and to induce bronchial challenge testing [3]. It is a short-acting beta2-adrenergic agonist that works by relaxing the smooth muscles in the airways, making it easier to breathe [3].
What Are the Potential Risks and Side Effects of Albuterol Inhalers?
Common side effects of albuterol inhalers include nervousness, tremor, dizziness, headache, nausea, and throat irritation. More serious, though less common, side effects can include paradoxical bronchospasm, allergic reactions, and cardiovascular effects such as increased heart rate and palpitations [3].
What is the Competitive Landscape for Albuterol Inhalers?
The market for albuterol inhalers is competitive, with Teva's ProAir HFA being a widely prescribed product. The potential entry of generic versions, such as the one proposed by Amneal, could significantly alter market dynamics and pricing [1]. Other generic albuterol inhalers are also available.
What is a Paragraph IV Certification?
A Paragraph IV certification is part of the Hatch-Waxman Act. It allows a generic drug manufacturer to challenge one or more patents listed in the U.S. Food and Drug Administration's (FDA) Orange Book for a brand-name drug. If the generic manufacturer demonstrates that the challenged patent is invalid or not infringed, it can pave the way for generic market entry [2].
What Is the Difference Between ProAir HFA and Other Albuterol Inhalers?
While albuterol is the active ingredient, different inhaler devices can affect delivery and patient experience. ProAir HFA uses a hydrofluoroalkane (HFA) propellant, which replaced chlorofluorocarbons (CFCs) due to environmental concerns. Other albuterol products may use different propellants or device types, such as Diskus or Respimat devices [3].
---
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration
[3] ProAir HFA Prescribing Information